Full Transition to Risk-Based GMP Oversight by MFDS
In 2026, South Korea's Ministry of Food and Drug Safety (MFDS) is making a comprehensive shift in pharmaceutical Good Manufacturing Practice (GMP) oversight—moving from inspection volume-driven monitoring to a risk assessment-based framework. This reform directly impacts approximately 1,200 domestic pharmaceutical manufacturers and represents a critical policy shift aimed at enhancing both global competitiveness and public safety.
A Fundamental Shift in Inspection Philosophy
Under the previous system, GMP inspections were conducted on a relatively uniform schedule based on facility size and predetermined timelines. The new framework evaluates manufacturers based on product risk classification, compliance history, and frequency of quality deviations, then applies differentiated inspection intensity and frequency accordingly. High-risk product manufacturers (sterile preparations, biologics, etc.) will face annual or more frequent in-depth inspections, while low-risk, high-compliance facilities may see inspection cycles extended up to three years.
Data-Driven, Site-Centric Management Structure
Integrated Data Management Across the Product Lifecycle
MFDS is building an integrated management platform that connects real-time data from raw material receipt through finished product release, distribution, and recall. Manufacturers must systematically accumulate deviation, change control, and CAPA (Corrective and Preventive Action) data, as these become core indicators in the risk assessment process.
Practical Application of Risk-Based Prioritization
The risk assessment framework operates on two axes: product risk and system risk. Product risk is determined by factors such as route of administration, sterility requirements, and API complexity. System risk reflects quality system maturity, historical findings, and voluntary recall history. The combined scores classify facilities into High, Medium, and Low tiers, which determine the scope and depth of regulatory inspections.
Practical Response Strategies for Pharma and Biotech Companies
Building an Internal Risk Assessment System
Companies need to establish internal risk assessment systems aligned with ICH Q9 (Quality Risk Management) guidelines. Applying FMEA (Failure Mode and Effects Analysis) or HACCP methodologies to GMP processes enables identification of risk factors at each manufacturing stage and quantification of residual risks.
Upgrading GMP Documentation and Data Management
Leveraging the 240-Day Fast-Track Biosimilar Approval Pathway
The 240-day expedited review timeline for biosimilars launching in 2026 creates significant opportunities when paired with risk-based management. Since pre-established GMP compliance is a prerequisite for fast-track approval, companies that proactively adopt risk assessment frameworks gain a clear advantage in approval timelines. This is also becoming a key evaluation criterion in CMO/CDMO contract negotiations with global pharmaceutical companies.
Practical Checklist and Consulting Services
Key Points for Risk Assessment Matrix Development
Redesigning Internal Audit Programs
---
KITIM (Korea Institute of Technology Innovation Management) provides end-to-end quality management support for pharmaceutical and biotech companies—from GMP certification consulting and risk assessment system design to biosimilar approval strategy. If your organization needs tailored consulting for the risk-based management transition, please reach out through our [Contact page](/contact) to schedule a consultation.